Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.63 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.57 |
| ▸ | ESR1 | P03372 | 4/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 7/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.51 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | MC4R | P32245 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyamphetamine SCHEMBL7041719 | 0.85 | TAAR1 (0.66) | SLC6A4TAAR1SLC6A2SLC6A3SIGMAR1 | |
| Pholedrine SCHEMBL2739157 | 0.83 | TAAR1 (0.63) | SLC6A4TAAR1SLC6A2ESR1ESR2 | |
| Pholedrine SCHEMBL119262 | 0.83 | TAAR1 (0.63) | SLC6A4TAAR1SLC6A2ESR1ESR2 | |
| Pholedrine SCHEMBL15286090 | 0.83 | TAAR1 (0.63) | SLC6A4TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL12907812 | 0.81 | TAAR1 (0.55) | SLC6A4TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL13996943 | 0.81 | CYP2D6 (0.66) | SLC6A4TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL3174249 | 0.80 | SIGMAR1 (0.65) | SLC6A4TAAR1CYP3A4CYP2D6TSHR | |
| SCHEMBL125441 | 0.80 | SIGMAR1 (0.65) | SLC6A4TAAR1CYP3A4CYP2D6TSHR | |
| SCHEMBL8441968 | 0.79 | SIGMAR1 (0.66) | SLC6A4TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL14521880 | 0.79 | SIGMAR1 (0.66) | SLC6A4TAAR1SLC6A2ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1692096-B1 | HYDROXYLAMINE DERIVATIVES | NEWRON PHARM SPA (IT) | 2013-04-03 | — | — | EP | claimed |
| US-20100197799-A1 | HYDROXYLAMINE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-08-05 | — | — | US | claimed |
| US-20070049643-A1 | Hydroxylamine derivatives | VICURON PHARMACEUTICALS INC. | 2007-03-01 | — | — | US | claimed |
| EP-1692096-A1 | HYDROXYLAMINE DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2006-08-23 | — | — | EP | claimed |
| WO-2005058800-A1 | HYDROXYLAMINE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-06-30 | — | — | WO | claimed |
| EP-1541547-A1 | Hydroxylamine derivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-06-15 | — | — | EP | claimed |
| EP-1692096-B1 | HYDROXYLAMINE DERIVATIVES | NEWRON PHARM SPA (IT) | 2013-04-03 | — | — | EP | disclosed |
| US-20100197799-A1 | HYDROXYLAMINE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-08-05 | — | — | US | disclosed |
| US-7763751-B2 | Hydroxylamine derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-07-27 | — | — | US | disclosed |
| US-20070049643-A1 | Hydroxylamine derivatives | VICURON PHARMACEUTICALS INC. | 2007-03-01 | — | — | US | disclosed |
| EP-1692096-A1 | HYDROXYLAMINE DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005058800-A1 | HYDROXYLAMINE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-06-30 | — | — | WO | disclosed |
| EP-1541547-A1 | Hydroxylamine derivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197799-A1 | HYDROXYLAMINE DERIVATIVES | C9, C1S, HTT | SLC6A4 629/4885TAAR1 718/4885SLC6A2 456/4885 |
| US-20070049643-A1 | Hydroxylamine derivatives | C9, C1S, HTT | SLC6A4 708/4885TAAR1 707/4885SLC6A2 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.